Expression of ER-α36, a novel variant of estrogen receptor in endometrial carcinoma and its clinical significance

Gynecologic and Obstetric Investigation

Volumn 75, Issue 1, 2013, Pages 68-72

  Sun, Lifang ^a,b   Wang, Jianliu ^a   Zhang, Lili ^b   Li, Xiaoping ^a   Shen, Danhua ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Beijing Jishuitan Hospital   (China)

Author keywords

Biomarker; Clinical significance; Endometrial carcinoma; Estrogen receptor 36

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA36; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR;

ADULT; AGE; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; CANCER STAGING; CARCINOGENESIS; CELL DIFFERENTIATION; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CORRELATIONAL STUDY; GENETIC VARIABILITY; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MYOMETRIUM; TUMOR INVASION; UTERINE CERVIX CANCER;

ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872597624     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000339933     Document Type: Article

References (15)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM: The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-839.
2. Mosselman S, Polman J, Dijkema R: ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49-53.
3. Pathirage N, Di Nezza LA, Salmonsen LA, Jobling T, Simpson ER, Clyne CD: Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer. Fertil Steril 2006; 86: 469-472.
4. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF: Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 2005; 336: 1023-1027.
5. Lee LM, Cao J, Deng H, Chen P, Gatalica Z, Wang ZY: ER-alpha36, a novel variant of ERalpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res 2008; 28: 479-483.
6. Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue (in German). Pathologe 1987; 8: 138-140.
7. Friedrichs K, Gluba S, Eidtmann H, Jonat W: Overexpression of p53 and prognosis in breast cancer. Cancer 1993; 72: 3641-3647.
8. Li L, Haynes MP, Bender JR: Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 2003; 100: 4807-4812.
9. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF: A variant of estrogen receptor-{alpha}, her-{alpha}36: transduction of estrogen-and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 2006; 103: 9063-9068.
10. Lin SL, Yan LY, Zhang XT, Yuan J, Li M, Qiao J, Wang ZY, Sun QY: ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3k/Akt pathways. PloS One 2010; 5:e9013.
11. Zheng Y, Zhang J, Xu ZZ, Sheng JM, Zhang XC, Wang HH, Teng XD, Liu XJ, Cao J, Teng LS: Quantitative profiles of the mRNAs of ER-alpha and its novel variant ER-alpha36 in breast cancers and matched normal tissues. J Zhejiang Univ Sci B 2010; 11: 144-150.
12. Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Wang Z, Xie Y: Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 2009; 27: 3423-3429.
13. He YY, Cai B, Yang YX, Liu XL, Wan XP: Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci 2009; 100: 1051-1061.
14. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, Prossnitz ER: GPR30: A novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 2007; 196: 386.e1-9, discussion 386.e9-e11.
15. Kang L, Zhang X, Xie Y, Tu Y, Wang D, Liu Z, Wang ZY: Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 2010; 24: 709-721.